The discussion explores how the rising burden of comorbidities and polypharmacy in patients with metastatic castration-sensitive prostate cancer requires clinicians to carefully balance therapy ...
Combining ¹⁷⁷Lu-rosopatamab tetraxetan with ARPIs or followed by docetaxel met primary safety/dosimetry objectives in a 36-patient international lead-in and supported feasibility within contemporary ...
Enzalutamide/leuprolide reduced metastasis or death versus leuprolide alone (HR 0.42) and improved overall survival (HR 0.597); enzalutamide monotherapy also improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results